Positron emission tomography in well-differentiated thyroid cancer

Thyroid Cancer (Second Edition): A Comprehensive Guide to Clinical Management

Volumn , Issue , 2006, Pages 319-328

  McDougall, I Ross ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70450173792     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-995-0_34     Document Type: Chapter

References (99)

1. Patton J, Turkington TG. Coincidence imaging with a dual-head scintillation camera. J Nucl Med 1999; 40:432-441.
2. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41:1177-1189.
3. Weihrauch MR, Dietlein M, Schicha H, et al. Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography in lym-phoma. Leuk Lymphoma 2003; 44: 15-22.
4. Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; 30(Suppl 1):S82-S88.
5. Moerlein SM, Mathis CA, Brennan KM, Budinger TF. Synthesis and in vivo evaluation of 122I-and 131I-labelled iodoperidol, a potential agent for the tomographic assessment of cerebral perfusion. Int J Rad Appl Instrum B 1987; 14:91-98.
6. Yasuda S, Ide M, Takagi S, Shohtsu A. Cancer screening w ith whole-body FDG PET. Kaku Igaku 1996; 33:1065-1071.
7. Yasuda S, Shohtsu A, Ide M, et al. Chronic thyroiditis: Diffuse uptake of FDG at PET. Radiology 1998; 207: 775-778.
8. Borner AR, Voth E, Wienhard K, et al. F-qi-FDG PET of the thyroid gland in Graves' disease. Nuklearmedizin 1998; 37:227-233.
9. Schmid DT, Kneifel S, Stoeckli SJ, et al. Increased 18F-FDG uptake mimicking thyroid cancer in a patient with Hashimoto's thyroiditis. Eur Radiol 2003; 13:2119-2121.
10. Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001; 130:941-946.
11. Kang KW, Kim SK, Kang HS, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003; 88: 4100-4104.
12. Ramos CD, Chisin R, Yeung HW, et al. Incidental focal thyroid uptake on FDG positron emission tomographic scans may represent a second primary tumor. Clin Nucl Med 2001; 26:193-197.
13. Adler LP, Bloom AD. Positron emission tomography of thyroid masses. Thyroid 1993; 3:195-200.
14. Uematsu H, Sadato N, Ohtsubo T, et al. Fluorine-18-fluorodeoxy-glucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. J Nucl Med 1998; 39:453-459.
15. Gianoukakis AG, Karam M, Cheema A, Cooper JA. Autonomous thyroid nodules visualized by positron emission tomography with (18)f-fluorodeoxyglucose: a case report and review of the literature. Thyroid 2003; 13:395-399.
16. Park CH, Lee EJ, Kim JK, et al. Focal F-18 FDG uptake in a nontoxic autonomous thyroid nodule. Clin Nucl Med 2002; 27:136-137.
17. Keyes JW, Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36:1836-1839.
18. Cook G, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Normal variants, artefacts and interpretative pitfalls in PET with 18-fluoro-2-deoxyglucose and carbon-11 methio-nine. Eur J Nucl Med 1999; 26:1363-1378.
19. Cook G, Wegner EA, Fogelman I. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med 2004; 34:122-133.
20. Barrington S, Maisey MN. Skeletal muscle uptake of fluorine-18 FDG: effect of oral diazepam. J Nucl Med 1996; 37:1127-1129.
21. Dobert N, Menzel C, Hamscho N, et al. Atypical thoracic and supra-clavicular FDG-uptake in patients with Hodgkin's and non-Hodgkin's lymphoma. Q J Nucl Med 2004; 48:33-38.
22. Hany TF, Gharehpapagh E, Kamel EM, et al. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging 2002; 29: 1393-1398.
23. Cohade C, Mourtzikos KA, Wahl RL. "USA-Fat": prevalence is related to ambient outdoor temperature-evaluation with 18F-FDG PET/CT. J Nucl Med 2003; 44:1267-1270.
24. Cohade C, Osman M, Pannu HK, Wahl RL. Uptake in supraclavicu-lar area fat ("USA-Fat"): description on 18F-FDG PET/CT. J Nucl Med 2003; 44:170-176.
25. Yeung HW, Grewal RK, Gonen M, et al. Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med 2003; 44: 1789-1796.
26. Tatsumi M, Engles JM, Ishimori T, et al. Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically. J Nucl Med 2004; 45: 1189-1193.
27. Igerc I, Kumnig G, Heinisch M, et al. Vocal cord muscle activity as a drawback to FDG-PET in the followup of differentiated thyroid cancer. Thyroid 2002; 12:87-89.
28. Zhu Z, Chou C, Yen TC, Cui R. Elevated F-18 FDG uptake in laryn-geal muscles mimicking thyroid cancer metastases. Clin Nucl Med 2001; 26:689-691.
29. Yeretsian RA, Blodgett TM, Branstetter BFT, et al. Teflon-induced granuloma: a false-positive finding w ith PET resolved with combined PET and CT. AJNR Am J Neuroradiol 2003; 24:1164-1166.
30. Alibazoglu H, Alibazoglu B, Hollinger EF, et al. Normal thymic uptake of 2-deoxy-2[F-18]fluoro-D-glucose. Clin Nucl Med 1999; 24: 597-600.
31. Kawano T, Suzuki A, Ishida A, et al. The clinical relevance of thymic fluorodeoxyglucose uptake in pediatric patients after chemotherapy. Eur J Nucl Med Mol Imaging 2004; 31:831-836.
32. Rini JN, Leonidas JC, Tomas MB, et al. FDG uptake in the anterior mediastinum. Physiologic thymic uptake or disease? Clin Positron Imaging 1999; 2:332.
33. Wittram C, Fischman AJ, Mark E, et al. Thymic enlargement and FDG uptake in three patients: CT and FDG positron emission tomography correlated with pathology. AJR Am J Roentgenol 2003; 180:519-522.
34. Nakahara T, Fujii H, Ide M, et al. FDG uptake in the morphologically normal thymus: comparison of FDG positron emission tomography and CT. Br J Radiol 2001; 74:821-824.
35. Patel PM, Alibazoglu H, Ali A, et al. Normal thymic uptake of FDG on PET imaging. Clin Nucl Med 1996; 21:772-725.
36. Pineda J, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80:1488-1492.
37. Schlumberger M, Mancusi F, B a udin E, Pacini F. 131I therapy for elevated thyroglobulin levels. Thyroid 1997; 7:273-276.
38. Wartofsky L. Management of scan negative thyroglobulin positive differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998; 83: 4195-4199.
39. McDougall I. 131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: What is being treated? Thyroid 1997; 7:669-672.
40. Fatourechi V, Hay ID, Javedan H, et al. Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab 2002; 87:1521-1526.
41. McDougall IR. Management of thyroglobulin positive/whole-body scan negative: is Tg positive/131I therapy useful? J Endocrinol Invest 2001; 24:194-198.
42. Hoefnagel B, Delprat CC, Marcuse HR, Vijlder JJM. Role of thallium-201 total-body scintigraphy in follow-up of thyroid carcinoma. J Nucl Med 1986; 27:1854-1857.
43. Iida Y, Hidaka A, Hatabu H, et al. Follow-up study of postoperative patients with thyroid cancer by thallium-201 scintigraphy and serum thyroglobulin measurement. J Nucl Med 1991; 32:2098-2100.
44. Nakada K, Katoh C, Kanegae E, et al. Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma. J Nucl Med 1998; 39:807-810.
45. Brandt-Mainz K, Muller SP, Reiners C, Bockisch A. Relationship between thyroglobulin and reliability of thallium 201 scintigraphy in differentiated thyroid cancer. Nuklearmedizin 2000; 39:20-25.
46. Yen TC, Lin HD, Lee CH, et al. The role of technetium-99m sestamibi whole-body scans in diagnosing metastatic Hurthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201 whole-body scans. E ur J Nucl Med 1994; 21: 980-983.
47. Almeida-Filho P, Ravizzini GC, Almeida C, Borges-Neto S. Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma. Clin Nucl Med 2000; 25:443-436.
48. Gallowitsch H, Mikosch P, Kresnik E, et al. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scin-tigraphy in differentiated thyroid carcinoma. J Nucl Med 1998; 39: 870-875.
49. Lind P, Gallowitsch HJ, Langsteger W, et al. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1997; 38:348-352.
50. Lind P. Multi-tracer imaging of thyroid nodules: is there a role in the preoperative assessment of nodular goiter? E ur J Nucl Med 1999; 26: 795-797.
51. Lind P, Gallowitsch HJ, Mikosch P, et al. Comparison of different tracers in the follow up of differentiated thyroid carcinoma. Acta Med Austriaca 1999; 26:115-117.
52. Drac-Kaniewska J, Kozlowicz-Gudzinska I, Tomaszewicz-Kubasik H, et al. 99mTc Tetrofosmin in diagnosis of distant metastases from differentiated thyroid cancer. Wiad Lek 2001; 54(Suppl 1):357-362.
53. Ahlman H, Tisell LE, Wangberg B, et al. The relevance of somato-statin receptors in thyroid neoplasia. Yale J Biol Med 1997; 70: 523-533.
54. Sarlis NJ, Gourgiotis L, Guthrie LC, et al. In-111 DTPA-octreotide scintigraphy for disease detection in metastatic thyroid cancer: comparison with F-18 FDG positron emission tomography and extensive conventional radiographic imaging. Clin Nucl Med 2003; 28:208-217.
55. Baudin E, Schlumberger M, Lumbroso J, et al. Octreotide scintigra-phy in patients with differentiated thyroid carcinoma; contribution for patients with negative radioiodine scans. J Clin Endocrinol Metab 1996; 81:2541-2544.
56. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987; 28:910-914.
57. Adams S, Baum RP, Hertel A, et al. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 1998; 25:1277-1283.
58. Adams S, Baum R, Rink T, et al. L imited value of fluorine-18 fluoro-deoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998; 25:79-83.
59. Alnafisi N, Driedger AA, Coates G, et al. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med 2000; 41:1010-1015.
60. Altenvoerde G, Lerch H, Kuwert T, et al. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg 1998; 383:160-163.
61. Berger F, Knesewitsch P, Tausig A, et al. [18F] Fluorodeoxyglucose hybrid PET in patients with differentiated thyroid cancer: Comparison with dedicated PET. Paris, France: Eur Ass Nucl Med Congress, 2000.
62. Boer A, Szakall S, Jr., Klein I, et al. FDG PET imaging in hereditary thyroid cancer. Eur J Surg Oncol 2003; 29:922-928.
63. Boerner AR, Petrich T, Weckesser E, et al. Monitoring isotretinoin therapy in thyroid cancer using 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002; 29:231-236.
64. Brandt-Mainz K, Muller SP, Gorges R, et al. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000; 27:490-496.
65. Macapinlac HA. Clinical usefulness of FDG PET in differentiated thyroid cancer. J Nucl Med 2001; 42:77-78.
66. Wong CO, Dworkin HJ. Role of FDG PET in metastatic thyroid cancer. J Nucl Med 1999; 40: 993-934.
67. Khan N, Oriuchi N, Higuchi T, et al. PET in the follow-up of differentiated thyroid cancer. Br J Radiol 2003; 76:690-695.
68. Crippa F, Alessi A, Gerali A, Bombardieri E. FDG-PET in thyroid cancer. Tumori 2003; 89:540-543.
69. Armstrong S, Worsley D, Blair GK. Pediatric surgical images: PET evaluation of papillary thyroid carcinoma recurrence. J Pediatr Surg 2002; 37:1648-1649.
70. Fiene ULR, Hanke JP, Wohrle H, Muller-Schauenburg W. 18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I. Nuclearmedizin 1995; 34: 127-134.
71. Shiga T, Tsukamoto E, Nakada K, et al. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 2001; 42:414-419.
72. Dietlein M, Moka D, Scheidhauer K, et al. Follow-up of differentiated thyroid cancer: comparison of multiple diagnostic tests. Nucl Med Commun 2000; 21:991-1000.
73. McDougall IR, Davidson J, Segall GM. Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl Med Commun 2001; 22:485-492.
74. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F]fluoro-deoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000; 85: 1107-1113.
75. Goshen E, Cohen O, Rotenberg G, et al. The clinical impact of 18F-FDG gamma PET in patients with recurrent well differentiated thyroid carcinoma. Nucl Med Commun 2003; 24:9599-9561.
76. Karwowski J, Jeffrey RB, McDougall IR, Weigel RJ. Intraoperative ultrasonography improves identification of recurrent thyroid cancer. Surgery 2002; 132:924-928.
77. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84:2291-2302.
78. Grunwald F, Schomburg A, Bender H, et al. Fluorine-18 fluoro-deoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996; 23:312-319.
79. Sisson JC, Ackermann RJ, Meyer MA, Wahl RL. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1993; 77:1090-1094.
80. Filetti S, Damante G, Foti D. Thyrotropin stimulates glucose transport in cultured rat thyroid cells. Endocrinology 1987; 120: 2576-2581.
81. Moog F, Linke R, Manthey N, et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000; 41:1989-1995.
82. Petrich T, Borner AR, Otto D, et al. Influence of rhTSH on [(18)F] fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002; 29:641-647.
83. Lambrecht RM, Woodhouse N, Phillips R, et al. Investigational study of iodine-124 with a positron camera. Am J Physiol Imaging 1988; 3:197-200.
84. Nahas Z, Goldenberg D, Fakhry C, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005; 115:237-243.
85. Pentlow KS, Graham MC, Lambrecht RM, et al. Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys 1991; 18:357-366.
86. Pentlow KS, Graham MC, Lambrecht RM, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med 1996; 37:1557-1562.
87. Flower M, Al-Saadi A, Harmer CL, et al. Dose response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy. Eur J Nucl Med 1994; 21:531-536.
88. Frey P, Townsend D, Jeavons A, Donath A. In vivo imaging of the human thyroid with a positron camera using I-124. In vivo imaging of the human thyroid with a positron camera using I-124. Eur J Nucl Med 1985; 10:472-476.
89. Frey P, Townsend D, Flattet A, et al. Tomographic imaging of the human thyroid using 124I. J Clin Endocrinol Metab 1986; 63: 918-927.
90. Crawford DC, Flower MA, Pratt BE, et al. Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography. E ur J Nucl Med 1997; 24:1470-1478.
91. Eschmann SM, Reischl G, Bilger K, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 2002; 29:760-767.
92. Sgouros G, Kolbert KS, Sheikh A, et al. Patient specific dosimetry for 131-I thyroid cancer therapy using 124-I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004; 45: 1366-1372.
93. Freudenberg LS, Antoch G, Gorges R, et al. Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report. Eur Radiol 2003; 13(Suppl 4):L19-L23.
94. Freudenberg LS, Antoch G, Jentzen W, et al. V a l ue of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 2004; 14:2092-2098.
95. Chung J-K, So Y, Lee JS, et al. V a l ue of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 1999; 40: 486-492.
96. Dietlein M, Scheidhauer K, Voth E, et al. Fluorine-18 fluoro-deoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24:1342-1348.
97. Grunwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxy-glucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999; 26:1547-1552.
98. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84:2291-2302.
99. Stokkel MP, de Klerk JH, Zelissen PM, et al. Fluorine-18 fluoro-deoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results. E ur J Nucl Med 1999; 26:1606-1609.